0001817048-21-000001.txt : 20210506
0001817048-21-000001.hdr.sgml : 20210506
20210506130321
ACCESSION NUMBER: 0001817048-21-000001
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20210506
DATE AS OF CHANGE: 20210506
EFFECTIVENESS DATE: 20210506
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Gilgamesh Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001817048
IRS NUMBER: 842552195
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-398477
FILM NUMBER: 21896862
BUSINESS ADDRESS:
STREET 1: 201 DAM TRAIL #1349
CITY: LINVILLE
STATE: NC
ZIP: 28646
BUSINESS PHONE: 347-967-6831
MAIL ADDRESS:
STREET 1: 201 DAM TRAIL #1349
CITY: LINVILLE
STATE: NC
ZIP: 28646
D
1
primary_doc.xml
X0708
D
LIVE
0001817048
Gilgamesh Pharmaceuticals, Inc.
113 University Place
Suite 1019
New York
NY
NEW YORK
10003
3479676831
DELAWARE
None
None
Corporation
true
2019
Jonathan
Sporn
113 University Place
Suite 1019
New York
NY
NEW YORK
10003
Executive Officer
Director
Andrew
Kruegel
113 University Place
Suite 1019
New York
NY
NEW YORK
10003
Executive Officer
Director
Robert
Berman
113 University Place
Suite 1019
New York
NY
NEW YORK
10003
Director
Dalibor
Sames
113 University Place
Suite 1019
New York
NY
NEW YORK
10003
Director
Sames resigned as a Director, effective upon closing of the transaction.
Amy
Kruse
P.O. Box 12829
Jackson
WY
WYOMING
83002
Director
Kruse was appointed as a Director, effective upon closing of the transaction.
Pharmaceuticals
Decline to Disclose
- 06b
false
2021-04-26
false
true
true
In addition to the shares of preferred stock sold by the Issuer, the shares of Issuer capital stock into which such shares of preferred stock may convert.
false
10000
34701891
34701837
54
false
66
0
0
630000
true
Some of the proceeds will be used to pay the salary of executive officers of the Issuer.
false
Gilgamesh Pharmaceuticals, Inc.
John Fallone /s/
John Fallone
Attorney for Issuer
2021-05-06